267 related articles for article (PubMed ID: 32346613)
1. Analysis of Lung Adenocarcinoma Subtypes Based on Immune Signatures Identifies Clinical Implications for Cancer Therapy.
Xu F; Chen JX; Yang XB; Hong XB; Li ZX; Lin L; Chen YS
Mol Ther Oncolytics; 2020 Jun; 17():241-249. PubMed ID: 32346613
[TBL] [Abstract][Full Text] [Related]
2. A signature-based classification of lung adenocarcinoma that stratifies tumor immunity.
Zhang X; Jiang D; Li S; Zhang X; Zheng W; Cheng B
Front Oncol; 2022; 12():1023833. PubMed ID: 36713530
[TBL] [Abstract][Full Text] [Related]
3. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment characterization identifies two lung adenocarcinoma subtypes with specific immune and metabolic state.
Huang J; Li J; Zheng S; Lu Z; Che Y; Mao S; Lei Y; Zang R; Liu C; Wang X; Fang L; Sun N; He J
Cancer Sci; 2020 Jun; 111(6):1876-1886. PubMed ID: 32187778
[TBL] [Abstract][Full Text] [Related]
5. Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for Immunotherapy.
Song Y; Yan S; Fan W; Zhang M; Liu W; Lu H; Cao M; Hao C; Chen L; Tian F; Zhan Y; Cai L; Xing Y
Front Cell Dev Biol; 2020; 8():550. PubMed ID: 32719796
[TBL] [Abstract][Full Text] [Related]
6. Characterization of lung adenocarcinoma based on immunophenotyping and constructing an immune scoring model to predict prognosis.
Liu M; Xiao Q; Yu X; Zhao Y; Qu C
Front Pharmacol; 2022; 13():1081244. PubMed ID: 36601052
[No Abstract] [Full Text] [Related]
7. Identification of an Immune Classification and Prognostic Genes for Lung Adenocarcinoma Based on Immune Cell Signatures.
Deng L; Long F; Wang T; Dai L; Chen H; Yang Y; Xie G
Front Med (Lausanne); 2022; 9():855387. PubMed ID: 35433762
[TBL] [Abstract][Full Text] [Related]
8. Classification of triple-negative breast cancers based on Immunogenomic profiling.
He Y; Jiang Z; Chen C; Wang X
J Exp Clin Cancer Res; 2018 Dec; 37(1):327. PubMed ID: 30594216
[TBL] [Abstract][Full Text] [Related]
9. TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival.
Freudenstein D; Litchfield C; Caramia F; Wright G; Solomon BJ; Ball D; Keam SP; Neeson P; Haupt Y; Haupt S
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545367
[TBL] [Abstract][Full Text] [Related]
10. m
Xu F; Huang X; Li Y; Chen Y; Lin L
Mol Ther Nucleic Acids; 2021 Jun; 24():780-791. PubMed ID: 33996259
[TBL] [Abstract][Full Text] [Related]
11. Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.
Dong ZY; Zhang C; Li YF; Su J; Xie Z; Liu SY; Yan LX; Chen ZH; Yang XN; Lin JT; Tu HY; Yang JJ; Zhou Q; Sun YL; Zhong WZ; Wu YL
J Thorac Oncol; 2018 Jan; 13(1):85-96. PubMed ID: 29127022
[TBL] [Abstract][Full Text] [Related]
12. Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling.
Zhou X; Qiu S; Nie L; Jin D; Jin K; Zheng X; Yang L; Wei Q
Front Oncol; 2020; 10():1429. PubMed ID: 32974156
[TBL] [Abstract][Full Text] [Related]
13. Precise Molecular Subtyping Reveals Heterogeneity of Lung Adenocarcinoma Based on DNA Methylation.
Shi J; Zhang M; Su M; Peng B; Xu R; Wang C; Zhou X; Zhang Y; Zhang L
Curr Med Chem; 2024 Jun; ():. PubMed ID: 38847255
[TBL] [Abstract][Full Text] [Related]
14. Immunogenomic Gene Signature of Cell-Death Associated Genes with Prognostic Implications in Lung Cancer.
Ahluwalia P; Ahluwalia M; Mondal AK; Sahajpal N; Kota V; Rojiani MV; Rojiani AM; Kolhe R
Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33466402
[TBL] [Abstract][Full Text] [Related]
15. Classification of Osteosarcoma Based on Immunogenomic Profiling.
Wang X; Wang L; Xu W; Wang X; Ke D; Lin J; Lin W; Bai X
Front Cell Dev Biol; 2021; 9():696878. PubMed ID: 34336848
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of a Novel Immune-Related Gene Signature in Lung Adenocarcinoma.
Feng H; Liang C; Shi Y; Liu D; Zhang J; Zhang Z
J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294477
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of tumor microenvironment-related genes of prognostic value in lung adenocarcinoma.
Yuan J; Yuan B; Zeng L; Liu B; Chen Y; Meng X; Sun R; Lv X; Wang W; Yang S
Oncol Lett; 2020 Aug; 20(2):1772-1780. PubMed ID: 32724420
[TBL] [Abstract][Full Text] [Related]
18. Identification of Lung Adenocarcinoma Subtypes Based on MHC-II Gene Expression Profile and Immunological Analysis.
Gao Y; Zhou L; Su Q; Li Q
Int Arch Allergy Immunol; 2024 Apr; ():1-16. PubMed ID: 38636483
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors.
Jang HJ; Lee HS; Ramos D; Park IK; Kang CH; Burt BM; Kim YT
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1598-1610.e3. PubMed ID: 31879171
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma.
Shi YX; Zhu T; Zou T; Zhuo W; Chen YX; Huang MS; Zheng W; Wang CJ; Li X; Mao XY; Zhang W; Zhou HH; Yin JY; Liu ZQ
Oncotarget; 2016 Dec; 7(51):85235-85243. PubMed ID: 27835911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
